[Outlook for the management of glioblastoma]

OUTLOOK FOR THE MANAGEMENT OF GLIOBLASTOMA. Glioblastoma is the most common primary malignant tumour of the central nervous system. The standard treatment consists of surgical resection, followed by concomitant radiochemotherapy and then six courses of adjuvant temozolomide. Tumour-Treating Fields (TTF) extend the median survival to twenty months, at the cost of constant use of a brace and alopecia. These patients require close neuro-oncological monitoring, with clinico-radiological reassessment every two to three months. In the event of progression, there is no standardised treatment, and the therapeutic arsenal is limited. Given that the disease usually progresses inevitably to major functional disability and death in the months or y ears following diagnosis, early supportive care is essential.